Our investigative team came across this press release for a novel immunomodulation trial for ovarian cancer. This trial will look at an aggressive combination of immunotherapy and PARP inhibitor olaparib.
Ultimovacs will test its experimental cancer vaccine UV1 as a triple-combination therapy for women with relapsed ovarian cancer who do not have mutations in their BRCA DNA repair genes. The Phase 2 DOVACC collaboration study is evaluating UV1 in combination with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) and PARP inhibitor Lynparza (olaparib) as maintenance therapy for women with high-grade ovarian cancer who respond to their second round of chemotherapy. The study is being carried out at over 30 clinical sites in 10 European countries.